Hualan Bacterin

Hualan Bacterin is a leading Chinese biopharmaceutical company specializing in the research, development, and large-scale manufacturing of human vaccines. As a major subsidiary of Hualan Biological Engineering, the company is recognized as the largest influenza vaccine producer in China and was the first in the country to receive approval for a quadrivalent influenza vaccine. Its commercial portfolio includes vaccines for rabies, hepatitis B, meningococcal meningitis, and tetanus, serving both the public and private immunization markets. Hualan Bacterin operates advanced GMP-certified facilities and is actively expanding its research into next-generation technologies, including mRNA-based vaccines and multi-valent conjugate vaccines. The company is publicly listed on the Shenzhen Stock Exchange and plays a critical role in China's public health infrastructure.